An international collaborative study has identified the E2F2 protein as a potential new therapeutic target to prevent metabolic fatty liver disease from progressing towards more serious conditions, such as cirrhosis or liver cancer. Read more
Medical News - Oct 22
Once almost exclusively seen in older adults, fatty liverdisease, which can be fatal if untreated, is now one of theworld’s fastest-growing diseases. And it’s increasinglyoccurring in young people as well. Read more
University At Buffalo - Oct 14
On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moder... Read more
Benzinga - Aug 18
